Answers are grounded in this paper and cite their sources.
This issue of the Journal of Clinical Oncology is devoted to gastrointestinal tumors. Pancreatic, gastric, colorectal, esophageal, and biliary tract tumors are discussed. Therapy, diagnostic modalities, and molecular markers are presented by experts in the oncology field. Readers will find the contents informative and, more importantly, very current. The latter was a top priority given to the authors so that the contents of the manuscripts would not be outdated. With regard to gastric cancer, two articles dealing with resectable disease are included. The first, by Soetikno et al, examines the role of endoscopic mucosal resection (EMR) for early disease. Although T1 tumors still comprise a relatively small percentage of the patients with gastric cancers seen in the United States, that percentage appears to be slowly increasing. The techniques of EMR are highly specialized, and few centers in the United States have significant experience with them. Nevertheless, given the excellent prognosis of appropriately selected patients, and the far superior quality of life with an intact stomach, EMR will likely see increasing application. Centers in which large numbers of patients are treated with this approach (primarily in Japan) are expanding the limits of what can be removed safely by this technique. The second article, by Jansen et al, examines more aggressive local therapy for gastric cancer. The role of extended lymphadenectomy in Western patients continues to simmer despite the failure of two prospective randomized trials to show a benefit. While these studies suffered from such high operative mortality from the extended resections that any potential benefit would be obscured, single centers routinely perform extended node dissections with mortality rates dramatically lower than that of the control arm of the randomized trials. A large prospective randomized trial of extended node dissections in Japan has completed accrual with a mortality rate of less than 1%. For some, the question of extended resections remains an issue given the highly positive results of the INT-0116 trial (utilizing chemoradiotherapy), in which many contend that substandard surgery was performed, implying that adjuvant therapy was simply making up for inadequate surgery. Perhaps the most important lesson out of this is that future studies of multimodality therapy for gastric cancer must pay at least as much attention to the surgical procedures performed as to the chemotherapy regimens and radiotherapy portals.
No takes yet. Share an insight, caveat, or question.
Petrelli et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: